Remicade® Granted Priority Review by U.S. Food and Drug Administration for Treatment of Ulcerative Colitis
Wed, 01 Jun 2005 06:00 PM EST
... First Biologic to Show Efficacy in Phase III Trials for Ulcerative Colitis - Centocor, Inc, announced today that the supplemental biologics license application (sBLA) for REMICADE® (infliximab) for the treatment of ulcerative colitis (UC) has been designated for priority review by the U... click link for more info. ...

Not Signed In -


